Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Nabriva Therapeutics
Nabriva Therapeutics
Activities:
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
How advanced technologies are unlocking the future of drug manufacturing
As the drug production landscape changes, it opens the door to pursue hybrid opportunities that push the boundaries of technological advancement in the field, reports Jon...
Andelyn Biosciences and Grace Science, LLC partner to manufacture AAV gene therapy
The partnership will seek to maximise programme efficiency, support the ongoing clinical trial and accelerate this critical therapy to patients
Teva UK and Closed Loop Medicine partner to advance personalised medicine development
SaMD platform aims to advance personalised medicine development, improve drug efficacy and patient outcomes with specific chronic conditions
Henkel facilities receive EXCiPACT certificate as suppliers of pharmaceutical excipients
The certification means Henkel meets EXCiPACT’s guidelines for good manufacturing practice (GMP) and good distribution practice (GDP)
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Pharmaceutical
Nabriva Therapeutics appoints Will Sargent as Vice President of Commercial Strategy and Investor Relations
He will lead development of commercial strategy for the launch of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP)
Research & Development
Elyse Seltzer joins Nabriva Therapeutics as Chief Medical Officer
Dr William Prince moves to Senior Vice President, Clinical Science
Infection Control
Nabriva Therapeutics secures financing of up to US$120m
To advance development of antibiotics for the treatment of infections caused by resistant gram-positive and gram-negative bacteria
Pharmaceutical
Nabriva Therapeutics strengthens board and management team
Charles Rowland and Dr Steven Gelone join the company
Research & Development
Nabriva Therapeutics hires Colin Broom as CEO
Also establishes new US subsidiary in the Philadelphia area
Subscribe now